nach oben

Targeted Oncology

Erschienen in:

01.03.2010 | Day-to-Day Practice

Complete remission of unresectable hepatocellular carcinoma treated with reduced dose of sorafenib: a case report

verfasst von: Sean Xiang Wang, Abigail Byrnes, Sadhna Verma, John R. Pancoast, Olivier Rixe

Erschienen in: Targeted Oncology | Ausgabe 1/2010

Einloggen, um Zugang zu erhalten

Abstract

Hepatocellular carcinoma (HCC) is a highly aggressive cancer. For patients who are diagnosed with advanced stage disease that are not surgical candidates, the disease is universally lethal. Advance has been made to extend survival with molecular target therapy, but durable complete responses are extremely rare. We report an unusual case where a 74-year-old patient with unresectable HCC received eight months of reduced-dose of sorafenib, a tyrosine kinase inhibitor, and achieved a durable complete remission. At the most recent follow up, he remains in remission 16 months after cessation of treatment, without clinical or imaging evidence of disease recurrence.

Parkin DM (2001) Global cancer statistics in the year 2000. Lancet Oncol 2(9):533–543CrossRefPubMed

Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359(4):378–390CrossRefPubMed

So BJ, Bekaii-Saab T, Bloomston MA, Patel T (2008) Complete clinical response of metastatic hepatocellular carcinoma to sorafenib in a patient with hemochromatosis: A case report. J Hematol Oncol 1:18CrossRefPubMed

Trevisani F, D’Intino PE, Morselli-Labate AM, Mazzella G, Accogli E, Caraceni P, Domenicali M, De Notariis S, Roda E, Bernardi M (2001) Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol 34(4):570–575CrossRefPubMed

Oquiñena S, Iñarrairaegui M, Vila JJ, Alegre F, Zozaya JM, Sangro B (2009) Spontaneous regression of hepatocellular carcinoma: three case reports and a categorized review of the literature. Dig Dis Sci 54(5):1147–1153CrossRefPubMed

Yoshida T, Hisamoto T, Akiba J et al (2006) Spreds, inhibitors of the Ras/ERK signal transduction, are dysregulated in human hepatocellular carcinoma and linked to the malignant phenotype of tumors. Oncogene 25:6056–6066CrossRefPubMed

Huynh H, Nguyen TT, Chow KH, Tan PH, Soo KC, Tran E (2003) Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: its role in tumor progression and apoptosis. BMC Gastroenterol 3:19CrossRefPubMed

Stock P, Monga D, Tan X, Micsenyi A, Loizos N, Monga SP (2007) Platelet-derived growth factor receptor-alpha: a novel therapeutic target in human hepatocellular cancer. Mol Cancer Ther 6:1932–1941CrossRefPubMed

Poon RT, Lau C, Pang R, Ng KK, Yuen J, Fan ST (2007) High serum vascular endothelial growth factor levels predict poor prognosis after radiofrequency ablation of hepatocellular carcinoma: importance of tumor biomarker in ablative therapies. Ann Surg Oncol 14:1835–1845CrossRefPubMed

10.

Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, Wilhelm S, Lynch M, Carter C (2006) Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 66(24):11851–11858CrossRefPubMed

11.

Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10(1):25–34CrossRefPubMed

12.

Houben R, Voigt H, Noelke C, Hofmeister V, Becker JC, Schrama D (2009) MAPK-independent impairment of T-cell responses by the multikinase inhibitor sorafenib. Mol Cancer Ther 8(2):433–440CrossRefPubMed

13.

Huitzel-Melendez FD, Saltz LB, Song J et al (2007) Retrospective analysis of outcome in hepatocellular carcinoma (HCC) patients with hepatitis C (C+) versus B (B+) treated with sorafenib (abstract). Data presented at the 2007 ASCO Gastrointestinal Cancers Symposium, January 19–21, 2007, Orlando, FL: (abstract 173)

14.

Bolondi L, Caspary W, Bennouna J et al (2008) Clinical benefit of sorafenib in hepatitis C patients with hepatocellular carcinoma (HCC): subgroup analysis of the SHARP trial (abstract). Data presented at the 2008 ASCO Gastrointestinal Cancers Symposium, January 25–27, 2008, Orlando, FL (abstract 129)

15.

Strumberg D, Richly H, Hilger RA, Schleucher N, Korfee S, Tewes M, Faghih M, Brendel E, Voliotis D, Haase CG, Schwartz B, Awada A, Voigtmann R, Scheulen ME, Seeber S (2005) Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 23(5):965–972CrossRefPubMed

Titel: Complete remission of unresectable hepatocellular carcinoma treated with reduced dose of sorafenib: a case report
verfasst von: Sean Xiang Wang
Abigail Byrnes
Sadhna Verma
John R. Pancoast
Olivier Rixe
Publikationsdatum: 01.03.2010
Verlag: Springer-Verlag
Erschienen in: Targeted Oncology / Ausgabe 1/2010
Print ISSN: 1776-2596
Elektronische ISSN: 1776-260X
DOI: https://doi.org/10.1007/s11523-010-0133-x

Neu im Fachgebiet Onkologie

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Complete remission of unresectable hepatocellular carcinoma treated with reduced dose of sorafenib: a case report

Abstract

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2010

The search for optimal response prediction in cancer leads to a personalized approach

Molecular response prediction in gastrointestinal stromal tumors

Dynamic contrast-enhanced ultrasonography (DCE-US): a new tool for the early evaluation of antiangiogenic treatment

Current challenges for the early clinical development of anticancer drugs in the era of molecularly targeted agents

Integrated molecular dissection of the epidermal growth factor receptor (EFGR) oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer

French Angiogenesis Society partners with Targeted Oncology

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie